Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study

BACKGROUND: We previously reported that biofilms and innate immunity contribute to the pathogenesis of Kawasaki disease. Therefore, we aimed to assess the efficacy of clarithromycin, an antibiofilm agent, in patients with Kawasaki disease. METHODS AND RESULTS: We conducted an open‐label, multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanishi, Etsuro, Nishio, Hisanori, Takada, Hidetoshi, Yamamura, Kenichiro, Fukazawa, Mitsuharu, Furuno, Kenji, Mizuno, Yumi, Saigo, Kenjiro, Kadoya, Ryo, Ohbuchi, Noriko, Onoe, Yasuhiro, Yamashita, Hironori, Nakayama, Hideki, Hara, Takuya, Ohno, Takuro, Takahashi, Yasuhiko, Hatae, Ken, Harada, Tatsuo, Shimose, Takayuki, Kishimoto, Junji, Ohga, Shouichi, Hara, Toshiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586277/
https://www.ncbi.nlm.nih.gov/pubmed/28684643
http://dx.doi.org/10.1161/JAHA.116.005370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586277/
https://www.ncbi.nlm.nih.gov/pubmed/28684643
http://dx.doi.org/10.1161/JAHA.116.005370

Ejemplares similares